New PET scan could replace biopsies for breast cancer patients
NCT ID NCT07294430
First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests a special PET scan that uses a radioactive tracer to track a protein called HER2 in the body. It aims to see if this imaging can predict how well a targeted cancer drug (T-DXd) works in 30 people with advanced breast cancer. The goal is to potentially replace invasive tumor biopsies with a simple scan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radioactive tracer [89Zr]-anti-HER2
- What this could lead to
- If successful, this imaging method could help doctors predict whether a targeted cancer drug is working without needing a tumor biopsy.
- What could go wrong
- This is a small, early-stage pilot study with only 30 participants, so results may not apply to all patients. The imaging technique is experimental and may not reliably predict treatment response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug YL202 targets Hard-to-Treat breast cancers
- Simple gloves and socks may shield breast cancer patients from chemo nerve pain
- New hope for advanced breast cancer: YL202 takes on standard treatments in major trial
- New drug shows promise in slowing advanced breast cancer with ESR1 mutation
- New hope for Drug-Resistant breast cancer: phase 3 trial launches
- New hope for advanced breast cancer: drug combo targets resistant tumors